Botanical species · safety record

Artemisia argyi

The EFSA Compendium of Botanicals holds 25 constituent measurements and 2 genotoxicity assays for Artemisia argyi. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Artemisia argyi H.Lév. & Vaniot

25Constituent measurements

2Safety records

8Cited sources

148Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 148 licensed products naming Artemisia argyi as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Dry
Extract Type TBA
decoction
solid

Source material stated

Leaf
Leaf (baked)
Leaf (fried with vinegar)
Leaf/Leaves
Root
Whole plant(s)
dried leaf (carbonized)

What the records describe

Constituents measured

Plant parts

Preparations

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Isoscopoletin	Leaves	Solvent extraction	—	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Scopoletin	Leaves	Solvent extraction	—	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
1,8-cineole	Aerial part of plants	Essential oil	20.45 Percent	GC-MS	No resolvable identifier
1,8-cineole	Aerial part of plants	Essential oil	≥ 14.32 Percent	GC-MS	No resolvable identifier
1,8-cineole	Aerial part of plants	Essential oil	≤ 26.12 Percent	GC-MS	No resolvable identifier
1,8-cineole	Aerial part of plants	Essential oil	22.19 Percent	GC-MS	No resolvable identifier
1,8-cineole	Aerial part of plants	Essential oil	7.22 Percent	GC-MS	No resolvable identifier
1,8-cineole	Leaves	Essential oil	49.09 Percent	GC-MS	No resolvable identifier
1,8-cineole	Leaves	Essential oil	28.59 Percent	GC-MS	No resolvable identifier
1,8-cineole	Leaves	Essential oil	≥ 13.75 Percent	GC-MS	No resolvable identifier
1,8-cineole	Leaves	Essential oil	≤ 18.26 Percent	GC-MS	No resolvable identifier
Alpha-thujone	Aerial part of plants	Essential oil	≤ 3.6 Percent	GC-MS	No resolvable identifier
Alpha-thujone	Aerial part of plants	Essential oil	≥ 0.32 Percent	GC-MS	No resolvable identifier
Artemisia ketone	Leaves	Essential oil	≥ 7.15 Percent	GC-MS	No resolvable identifier
Artemisia ketone	Aerial part of plants	Essential oil	3.44 Percent	GC-MS	No resolvable identifier
Artemisia ketone	Leaves	Essential oil	≤ 12.15 Percent	GC-MS	No resolvable identifier
Artemisia ketone	Aerial part of plants	Essential oil	5.85 Percent	GC-MS	No resolvable identifier
Camphor	Aerial part of plants	Essential oil	10.39 Percent	GC-MS	No resolvable identifier
Camphor	Leaves	Essential oil	4.64 Percent	GC-MS	No resolvable identifier
Camphor	Leaves	Essential oil	3.82 Percent	GC-MS	No resolvable identifier
Camphor	Aerial part of plants	Essential oil	≥ 3.66 Percent	GC-MS	No resolvable identifier
Camphor	Aerial part of plants	Essential oil	6.99 Percent	GC-MS	No resolvable identifier
Camphor	Aerial part of plants	Essential oil	≤ 14.97 Percent	GC-MS	No resolvable identifier
Eugenol	Aerial part of plants	Essential oil	2.26 Percent	GC-MS	No resolvable identifier
Filifolone	Aerial part of plants	Essential oil	7.29 Percent	GC-MS	No resolvable identifier

Genotoxicity testing

Outcomes of genotoxicity assays as recorded in the source. A negative assay is a result under those test conditions, not a clearance.

Outcome	Endpoint	Test	Tested organism	Metabolic activation	Source
Positive	chromosome aberration	micronucleus assay	House mouse (as animal)	—	No resolvable identifier
Positive	DNA damage and/or repair	other	House mouse (as animal)	Not applicable	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Lan, Mei-bing., Yu, Yong-li., Lu, Wei., Liu, Mao-sheng., Zheng, Yan-fang., Yang, Hui-ying., Li, Xiao-hong. Chemical constituents and genotoxicity of volatile oil in Artemisia argyi from Gansu.. Zhongguo shiyan fangjixue zazhi, 2012, vol. 18, no. 13, p. 252-255.
Wen, Fuji., Yoo, Kyungseun., Eom, Minseop. Chemical composition of essential oil of Artemisia argyi.. Xiangliao xiangjing huazhuangpin, 2007, no. 3, p. 21-23.
Zhang, Shi-xian., Yu, Yong-hua., Ao, Ke-hou., Zeng, Qi-hua. GC-MS determination of components of volatile oil in Artemisia argyi.. Lihua jianyan, huaxue fence, 2013, vol. 49, no. 6, p. 705-708.
Lan, Meibing., Yu, Yongli., Li, Xiaohong. Analysis on chemical constituents of essential oil of Artemisia argyi Levl. et Vant. in Guizhou.. Yaowu fenxi zazhi, 2009, vol. 29, no. 8, p. 1305-1308.
Wang, Yonglin., Liu, Laping. Analysis of the volatile constituents of Artemisia argyi by SPME/GC/MS.. Xibei yaoxue zazhi, 2009, vol. 24, no. 5, p. 354-357.
Zhao, Zhi-hong., Huang, Yong-yong., Zhang, Xiao-jun., Wang, Li-yang., Zhang, Zhuang-li., Wang, Gui-fang. GC-MS analysis of essential oil of artemisia argyi from Zhumadian in Henan Province.. Zhengzhou daxue xuebao, lixueban, 2013, vol. 45, no. 2, p. 80-84.
Hao, Peng-fei., Zhang, Li-fang., Zhang, Chao-yun., Huang, Xian-zhang. Comparative analysis GC-MS of Artemisiae Argyi Folium volatile oil extracted by SPME and SFE.. Zhongguo shiyan fangjixue zazhi, 2014, vol. 20, no. 23, p. 68-71.
Adams, Michael., Efferth, Thomas., Bauer, Rudolf. Activity-guided isolation of scopoletin and isoscopoletin, the inhibitory active principles towards CCRF-CEM leukaemia cells and multi-drug resistant CEM/ADR5000 cells, from Artemisia argyi. PLANTA MEDICA, 2006, vol. 72, no. 9, p. 862-864. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature